Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
2025-522831-33-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Zasocitinib with Placebo (2 arms). Primary endpoint: HiSCR75 at Week 16. Planned start May 2026; status: authorised.
02
Drugs
zasocitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-522831-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522831-33-00.